MARC Record from Harvard University

LEADER: 03529cam a2200433 a 4500
001 001322583-9
005 20020606090541.3
008 870706s1987 nyua b 10110 eng d
010 $a 87020260
020 $a0306425882
035 0 $aocm16227183
040 $aDNLM/DLC$cDLC$dOCL$dHMS
050 0 $aRC694.3$b.I575 1986
060 00 $aW1$bAD559 v.214 1987
060 10 $aQV 193$bI614n 1986
082 0 $a616.1/35061$219
111 2 $aInternational Symposium on the New Dimensions of Warfarin Prophylaxis$d(1986 :$cNew York University Medical Center)
245 14 $aThe new dimensions of warfarin prophylaxis /$cedited by Stanford Wessler, Carl G. Becker, and Yale Nemerson.
260 0 $aNew York :$bPlenum Press,$cc1987.
300 $aix, 329 p. :$bill. ;$c26 cm.
440 0 $aAdvances in experimental medicine and biology ;$vv. 214
500 $a"Proceedings of the International Symposium on the New Dimensions of Warfarin Prophylaxis, held October 16-18, 1986, at the New York University Medical Center in New York"--T.p. verso.
504 $aIncludes bibliographies and index.
520 $aThe International Symposium on The New Dimensions of Warfarin Prophylaxis held on October 16-18, 1986, in New York City was conceived as a forum to bring together physicians and other scientists knowledgeable about the pharmacological effects of warfarin on the hemostatic mechanism and the clinical usefulness of this compound in the prevention of thromboembolic phenomena. The coumarin compounds have commanded a striking breadth of interest among members of the biomedical research community for almost one-half century. Aspects of its effects on the Vitamin K-dependent proteins, on the laboratory recognition of the drug's pharmacologic action and its use as a therapeutic agent in a variety of disease states have been actively studied with increasing intensity in the past several decades. Thus, the present state of these studies seemed to be a timely subject for discussion, not only to gather together in one place representative samples of the myriad of data on warfarin, but also to underscore the every increasing necessity for communication between basic research and clinical practice. The content and organization of this monograph reflect the scope and importance of warfarin prophylaxis. One of the unique aspects of this publication is that it spells out in one place the warfarin story from molecular biology through clinical trials to future directions of research and patient care.
650 2 $aThromboembolism$xprevention & control$xcongresses.
650 2 $aWarfarin$xpharmacology$xcongresses.
650 2 $aWarfarin$xtherapeutic use$xcongresses.
650 0 $aWarfarin$vCongresses.
650 0 $aThrombolytic therapy$vCongresses.
650 0 $aThrombosis$xPrevention$vCongresses.
655 7 $aConference proceedings.$2fast
700 1 $aWessler, Stanford,$d1917-
700 1 $aBecker, Carl G.
700 1 $aNemerson, Yale.
700 1 $aWessler, Stanford,$d1917-2005.
776 08 $iOnline version:$aInternational Symposium on the New Dimensions of Warfarin Prophylaxis (1986 : New York University Medical Center)$tNew dimensions of warfarin prophylaxis.$dNew York : Plenum Press, c1987$w(OCoLC)747326729
776 08 $iOnline version:$aInternational Symposium on the New Dimensions of Warfarin Prophylaxis (1986 : New York University Medical Center).$tNew dimensions of warfarin prophylaxis.$dNew York : Plenum Press, ©1987$w(OCoLC)747326729
988 $a20020608
906 $0OCLC